治疗目标和个性化医学在心脏病中的治疗目标和个性化医学
Elizabeth Vafiadaki1, Irene C Turnbull2, Despina Sanoudou1,3,4
1Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece.
Journal of personalized medicine
|November 25, 2023
概括
心血管疾病 (CVD) 研究继续进步,但它仍然是全球主要的死亡原因. 进一步的研究对于应对这种持续的健康挑战至关重要.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 医学研究 医学研究
背景情况:
- 心血管疾病 (CVD) 是全球主要的健康问题,也是全球死亡的主要原因.
- 尽管有数十年的研究和进步,心血管疾病仍然影响着全球数百万人.
- 持续需要创新的策略来应对心血管疾病的持续负担.
研究的目的:
- 审查心血管疾病 (CVD) 研究的最新进展.
- 确定心血管疾病预防和治疗的持续挑战和未来方向.
- 强调持续对心血管健康进行科学调查的迫切需要.
主要方法:
- 关于心血管疾病 (CVD) 的最新研究的综合文献综述.
- 分析与心脏病相关的全球死亡率和发病率数据.
- 综合发现,以确定关键的研究差距和治疗机会.
主要成果:
- 在了解心血管疾病机制方面取得了重大进展.
- 然而,心血管疾病仍然是全球首要的死亡原因.
- 将研究成果转化为广泛的临床实践仍然是一个挑战.
结论:
- 持续的研究和开发对于克服心血管疾病 (CVD) 的全球负担至关重要.
- 需要多学科的方法来加速CVD预防和管理的进展.
- 加强全球合作可以推动心血管医学的创新.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594


